Anixa Biosciences (ANIX) and Moffitt Cancer Center File IND Application for Ovarian Cancer CAR-T Therapy
- Dow hits milestone, S&P breaks record high on tech rally
- Thermo Fisher Scientific (TMO) to Acquire PPD, Inc. (PPD) for $47.50/sh, $17.4 Billion
- U.S. retail sales post largest gain in 10 months; weekly jobless claims fall
- Dell (DELL) Gains on Spin-Off of its 81% Stake in VMware (VMW), Analysts Bulled-Up as It Could Unlock $20 Per Share of Value for DELL
- The Stock Market is Almost 'Completely Broken' - Einhorn
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that an IND (Investigational New Drug) application for its ovarian cancer CAR-T (Chimeric Antigen Receptor T-cell) therapy has been filed with the U.S. Food and Drug Administration.
This CAR-T therapy was invented by a team led by Dr. Jose Conejo-Garcia, while he was at the Wistar Institute. Dr. Conejo-Garcia is currently Chair of the Department of Immunology at Moffitt Cancer Center (MCC), where the IND enabling studies were performed, and where the clinical trial will be conducted, under the leadership of Dr. Robert Wenham, Chair of Gynecological Oncology at MCC. Anixa has a worldwide, exclusive commercial license to the technology.
The technology targets the follicle stimulating hormone receptor (FSHR) with engineered T-cells that use the follicle stimulating hormone as a homing mechanism. FSHR is found at immunological levels exclusively on the granulosa cells of the ovaries. Since the target is a hormone receptor, this technology is also known as CER-T (Chimeric Endocrine Receptor T-cell) therapy, a new type of CAR-T.
Dr. Wenham stated, "We are pleased to file this IND application, since women who have recurrent ovarian cancer have very few options. We hope the work of our scientific and clinical team at Anixa and MCC yields results that will address a critical unmet medical need."
"We are looking forward to the response from the FDA, and to eventually testing this therapy in humans," stated Dr. Conejo-Garcia. "This is a very high-profile program at MCC, as we believe this could be the first CAR-T therapy that has the potential to achieve clinical success in a solid tumor indication."
"This IND application is a major milestone for Anixa and our partners at MCC," stated Dr. Amit Kumar, President and CEO of Anixa Biosciences. "This is our second IND application filed within the last few months. Upon clearance from the FDA and commencement of the trial, we expect to have two programs in the clinic."
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: IDEAYA Biosciences (IDYA) Reports First Patient Dosing in Phase 1 Clinical Trial of MAT2A Inhibitor IDE397 Evaluating MTAP-Deletion Solid Tumors
- FibroGen (FGEN) Receives Rare Pediatric Disease Designation from the U.S. FDA for Pamrevlumab for Treatment of DMD
- GSK (GSK) and Vir Biotechnology (VIR) Announce EMA Review of Dual-Action Monoclonal Antibody VIR-7831 for the Early Treatment of COVID-19
Create E-mail Alert Related CategoriesCorporate News, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!